Review article · 2022 · Open access

Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update

Sun Ah Park, Yu Jung Jang, Min Kyoung Kim, Sun Min Lee, So Young Moon

Journal of Clinical Neurology, 18(4), 401 · Published 1 July 2022 · DOI 10.3988/jcn.2022.18.4.401

Open full textCite this paper

In brief

“Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update” is a 2022 review article by Sun Ah Park and 4 co-authors, published in Journal of Clinical Neurology. OpenAlex counts 50 citations as of 19 November 2026, which puts it in the top 3% of works published in 2022 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Journal of Clinical Neurology.

Citations
50
Most cited in
2024 (16)
Field-weighted impact
1.18
References
75
Authors
5

Abstract

Alzheimer's disease (AD) is the most-common cause of neurodegenerative dementia, and it is characterized by abnormal amyloid and tau accumulation, which indicates neurodegeneration. AD has mostly been diagnosed clinically. However, ligand-specific positron emission tomography (PET) imaging, such as amyloid PET, and cerebrospinal fluid (CSF) biomarkers are needed to accurately diagnose AD, since they supplement the shortcomings of clinical diagnoses. Using biomarkers that represent the pathology of AD is essential (particularly when disease-modifying treatment is available) to identify the corresponding pathology of targeted therapy and for monitoring the treatment response. Although imaging and CSF biomarkers are useful, their widespread use is restricted by their high cost and the discomfort during the lumbar puncture, respectively. Recent advances in AD blood biomarkers shed light on their future use for clinical purposes. The amyloid β (Aβ)42/Aβ40 ratio and the concentrations of phosphorylated tau at threonine 181 and at threonine 217, and of neurofilament light in the blood were found to represent the pathology of Aβ, tau, and neurodegeneration in the brain when using automatic electrochemiluminescence technologies, single-molecule arrays, immunoprecipitation coupled with mass spectrometry, etc. These blood biomarkers are imminently expected to be incorporated into clinical practice to predict, diagnose, and determine the stage of AD. In this review we focus on advancements in the measurement technologies for blood biomarkers and the promising biomarkers that are approaching clinical application. We also discuss the current limitations, the needed further investigations, and the perspectives on their use.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M., & Moon, S. Y. (2022). Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update. Journal of Clinical Neurology, 18(4), 401. https://doi.org/10.3988/jcn.2022.18.4.401

MLA 9

Park, Sun Ah, et al. “Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update.” Journal of Clinical Neurology, vol. 18, no. 4, 2022, p. 401. https://doi.org/10.3988/jcn.2022.18.4.401.

Chicago

Park, Sun Ah, Yu Jung Jang, Min Kyoung Kim, Sun Min Lee, and So Young Moon. 2022. “Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update.” Journal of Clinical Neurology 18 (4): 401. https://doi.org/10.3988/jcn.2022.18.4.401.

Harvard

Park, S. A. et al. (2022) ‘Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update’, Journal of Clinical Neurology, 18(4), p. 401. doi:10.3988/jcn.2022.18.4.401.

IEEE

S. A. Park, Y. J. Jang, M. K. Kim, S. M. Lee, and S. Y. Moon, “Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update,” Journal of Clinical Neurology, vol. 18, no. 4, p. 401, 2022, doi: 10.3988/jcn.2022.18.4.401.

BibTeX

@article{park2022promising,
  title     = {{Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update}},
  author    = {Park, Sun Ah and Jang, Yu Jung and Kim, Min Kyoung and Lee, Sun Min and Moon, So Young},
  journal   = {Journal of Clinical Neurology},
  year      = {2022},
  volume    = {18},
  number    = {4},
  pages     = {401},
  doi       = {10.3988/jcn.2022.18.4.401},
  url       = {https://doi.org/10.3988/jcn.2022.18.4.401}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202255
202388
20241616
20251313
202688

Its field-weighted citation impact is 1.18: it has been cited 1.18 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • blood biomarkers
  • amyloid-beta 42/40 ratio
  • phosphorylated tau
  • neurofilament light chain
  • amyloid accumulation
  • tau accumulation
  • neurodegeneration

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M., & Moon, S. Y. (2022). Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update. Journal of Clinical Neurology, 18(4), 401. https://doi.org/10.3988/jcn.2022.18.4.401

How many times has this paper been cited?

50 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Clinical Neurology: sign in and open the full text from this page.

Who wrote this paper?

Sun Ah Park, Yu Jung Jang, Min Kyoung Kim, Sun Min Lee, So Young Moon.

What is the DOI of this paper?

10.3988/jcn.2022.18.4.401, permanently at https://doi.org/10.3988/jcn.2022.18.4.401. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.